Dapagliflozin and Metformin Hydrochloride Earn EU Approval as Xigduo

Dapagliflozin and Metformin Hydrochloride Earn EU Approval as XigduoOn January 24, 2014 the European Commission announced their marketing authorization to both AstraZeneca and Bristol-Myers Squibb for Xigduo. As a powerful medication for type 2 diabetes, Xigduo is a combination of Dapagliflozin and Metformin Hydrochloride, and available in two dosages: 5mg/850mg and 5mg/1,000mg tablets, respectively. This dynamic duo of powerhouse anti-diabetic medications is designed to be taken twice daily, and they offer optimal glycemic control through their complementary mechanisms of action.

The addition of this Dapagliflozin and Metformin Hydrochloride combination product in the type 2 diabetes pharmaceutical market is exciting for the patient population suffering from hard to control type 2 diabetes. Many patients are currently taking Metformin and Dapagliflozin adjunctively but separately, so combining these two treatments into one tablet makes dosing easier and more tolerable for patients. Dapagliflozin, also known as the brand name Farxiga was the first medicine in the SGLT2 class to gain regulatory approval, and was recently approved by the FDA in mid-January 2014. As a sodium-glucose co-transporter that is mainly found in the kidney, SGLT2 is responsible for a large portion of glucose re-absorption in the body. This SGLT2 situation is challenging for patients with type 2 diabetes, as the ability of their the kidney to reabsorb glucose is already increased by roughly 20%, which often leads to exaggerated hyperglycemia.

Sodium-glucose transport proteinsThis novel Dapagliflozin and Metformin Hydrochloride combination is helpful for meeting the diverse needs of the growing patient population suffering from type 2 diabetes. Xigduo {Dapagliflozin and Metformin Hydrochloride} offers a personalized and efficacious option for treatment that patients will find tolerable and effective for controlling their glycemic levels. Practitioners and pharmacists also recommend a healthy lifestyle, optimal diet and regular exercise as important components for patients being treated with the Dapagliflozin and Metformin combination as well.

LGM Pharma provides both Dapagliflozin CAS# 461432-26-8 and Metformin Hydrochloride CAS# 1115-70-4 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share: